GabonTuberculosis profile
Population  2014 1.7 million
Estimates of TB burden * 2014 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.94 (0.66–1.3) 55 (39–75)
Mortality (HIV+TB only) 0.3 (0.24–0.37) 18 (14–22)
Prevalence  (includes HIV+TB) 10 (5.2–17) 615 (309–1 025)
Incidence  (includes HIV+TB) 7.5 (6.6–8.4) 444 (393–497)
Incidence (HIV+TB only) 0.53 (0.46–0.61) 32 (27–36)
         
Case detection, all forms (%) 75 (67–84)    
Estimates of MDR-TB burden * 2014   New   Retreatment
% of TB cases with MDR-TB 2.2 (0.3–4.1) 11 (6.2–16)
MDR-TB cases among notified pulmonary
TB cases
110 (15–200) 100 (57–140)
TB case notifications 2014 New ** Relapse
Pulmonary, bacteriologically confirmed 2 184   222
Pulmonary, clinically diagnosed 2 754   0
Extrapulmonary 448   0
       
Total new and relapse 5 608    
Previously treated, excluding relapses 691    
Total cases notified 6 299    
Among 5 608 new and relapse cases:
463 (8%) cases aged under 15 years; male:female ratio: 1.3
Reported cases of RR-/MDR-TB 2014 New Retreatment Total **
Cases tested for RR-/MDR-TB 58 (3%) 2 (<1%) 308
Laboratory-confirmed RR-/MDR-TB cases     59
Patients started on MDR-TB treatment ***     0
TB/HIV 2014 Number (%)
TB patients with known HIV status 2 504 (40)
HIV-positive TB patients 648 (26)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 511 (79)
HIV-positive TB patients on antiretroviral therapy (ART) 511 (79)
HIV-positive people screened for TB 574  
HIV-positive people provided with IPT 0  
Treatment success rate and cohort size (%) Cohort
New and relapse cases registered in 2013 (55) 3 861
Previously treated cases, excluding relapse, registered in 2013 (41) 628
HIV-positive TB cases, all types, registered in 2013    
RR-/MDR-TB cases started on second-line treatment in 2012    
XDR-TB cases started on second-line treatment in 2012    
Laboratories 2014  
Smear (per 100 000 population) 1.0
Culture (per 5 million population) 3.0
Drug susceptibility testing (per 5 million population) 0
Sites performing Xpert MTB/RIF 3
Is second-line drug susceptibility testing available? No
Financing TB control 2015  
National TB programme budget (US$ millions) 1.5
% Funded domestically 75%
% Funded internationally 2%
% Unfunded 23%
* Ranges represent uncertainty intervals
** Includes cases with unknown previous TB treatment history
*** Includes patients diagnosed before 2014 and patients who were not laboratory-confirmed as having
RR-/MDR-TB
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
   Prevalence

(Rate per 100 000 population per year)
Incidence graph
   Notified (new and relapse)   Incidence
   Incidence (HIV+TB only)

(Number of patients)
CPT ART graph
   HIV-positive TB patients
   on CPT   on ART

Treatment success rate (%)
tx success graph
   New   Retreatment
   New and relapse   Retreatment, excluding
relapse
   HIV-positive   RR-/MDR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Funded domestically__Funded internationally
__Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2016-07-26 Data: www.who.int/tb/data